-
Something wrong with this record ?
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society
AR. Lyon, S. Dent, S. Stanway, H. Earl, C. Brezden-Masley, A. Cohen-Solal, CG. Tocchetti, JJ. Moslehi, JD. Groarke, J. Bergler-Klein, V. Khoo, LL. Tan, MS. Anker, S. von Haehling, C. Maack, R. Pudil, A. Barac, P. Thavendiranathan, B. Ky, TG....
Language English Country Great Britain
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
06/303/98
Department of Health - United Kingdom
P30 CA008748
NCI NIH HHS - United States
R01 CA233610
NCI NIH HHS - United States
R01 HL141466
NHLBI NIH HHS - United States
NLK
Medline Complete (EBSCOhost)
from 2000-03-01 to 1 year ago
Wiley Free Content
from 1999 to 1 year ago
PubMed
32463967
DOI
10.1002/ejhf.1920
Knihovny.cz E-resources
- MeSH
- Androgen Antagonists adverse effects therapeutic use MeSH
- Risk Assessment methods MeSH
- Cardiovascular Diseases * diagnosis epidemiology physiopathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasms * drug therapy epidemiology physiopathology MeSH
- Antineoplastic Agents * adverse effects therapeutic use MeSH
- Heart Disease Risk Factors MeSH
- Risk Factors MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Barts Heart Centre and University College London London UK
Breast Unit Royal Marsden Hospital Surrey UK
Cardio Oncology Center of Excellence Washington University in St Louis St Louis MO USA
Cardio Oncology Department of Cardio Pneumology University of São Paulo São Paulo Brazil
Cardio Oncology Program Brigham and Women's Hospital Harvard Medical School Boston MA USA
Cardio Oncology Program Department of Medicine Vanderbilt University Medical Center Nashville TN USA
Cardio Oncology Service Royal Brompton Hospital and Imperial College London UK
Cardioncology Unit European Institute of Oncology IRCCS Milan Italy
Comprehensive Heart Failure Center University Clinic Würzburg Würzburg Germany
Department of Cardiology and Angiology Hannover Medical School Hannover Germany
Department of Cardiology and Pneumology University of Goettingen Medical Center Goettingen Germany
Department of Cardiology Bern University Hospital Inselspital University of Bern Bern Switzerland
Department of Cardiology Medical University of Vienna Vienna Austria
Department of Cardiovascular Diseases Mayo Clinic Rochester MN USA
Department of Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research London UK
Department of Haematological Medicine King's College Hospital London UK
Department of Haematology Hammersmith Hospital Imperial College London UK
Department of Precision Medicine Luigi Vanvitelli University of Campania Naples Italy
Division of Medical Oncology Sinai Health System Mount Sinai Hospital Toronto Canada
Duke Cancer Institute Duke University Durham NC USA
Emergency Institute for Cardiovascular Diseases 'Prof C C Iliescu' Bucharest Romania
Faculty of Medicine and Serbian Academy of Sciences and Arts University of Belgrade Belgrade Serbia
German Center for Cardiovascular Research partner site Goettingen Goettingen Germany
Liverpool Centre for Cardiovascular Science Liverpool Heart and Chest Hospital Liverpool UK
MedStar Heart and Vascular Institute Georgetown University Washington DC USA
Memorial Sloan Kettering Cancer Center New York NY USA
National Amyloidosis Centre University College London London UK
Pharmacology Centre of Clinical and Experimental Medicine IRCCS San Raffaele Pisana Rome Italy
Santa Cardio Oncology Santa Casa de São Paulo and Rede Dor São Luiz São Paulo Brazil
Sechenov Medical University Moscow Russia
Stanford University School of Medicine Stanford CA USA
UMR S 942 Paris University Cardiology Department Lariboisiere Hospital AP HP Paris France
University Heart Center Department of Cardiology University Hospital Zurich Zurich Switzerland
University of Cyprus Medical School Nicosia Cyprus
University of Medicine Carol Davila Bucharest Romania
University of Pennsylvania Philadelphia PA USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019880
- 003
- CZ-PrNML
- 005
- 20230131100513.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ejhf.1920 $2 doi
- 035 __
- $a (PubMed)32463967
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Lyon, Alexander R $u Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK
- 245 10
- $a Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society / $c AR. Lyon, S. Dent, S. Stanway, H. Earl, C. Brezden-Masley, A. Cohen-Solal, CG. Tocchetti, JJ. Moslehi, JD. Groarke, J. Bergler-Klein, V. Khoo, LL. Tan, MS. Anker, S. von Haehling, C. Maack, R. Pudil, A. Barac, P. Thavendiranathan, B. Ky, TG. Neilan, Y. Belenkov, SD. Rosen, Z. Iakobishvili, AL. Sverdlov, LA. Hajjar, AVS. Macedo, C. Manisty, F. Ciardiello, D. Farmakis, RA. de Boer, H. Skouri, TM. Suter, D. Cardinale, RM. Witteles, MG. Fradley, J. Herrmann, RF. Cornell, A. Wechelaker, MJ. Mauro, D. Milojkovic, H. de Lavallade, F. Ruschitzka, AJS. Coats, PM. Seferovic, O. Chioncel, T. Thum, J. Bauersachs, MS. Andres, DJ. Wright, T. López-Fernández, C. Plummer, D. Lenihan
- 520 9_
- $a This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antagonisté androgenů $x škodlivé účinky $x terapeutické užití $7 D000726
- 650 12
- $a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 12
- $a kardiovaskulární nemoci $x diagnóza $x epidemiologie $x patofyziologie $7 D002318
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a rizikové faktory kardiovaskulárních chorob $7 D000082742
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a nádory $x farmakoterapie $x epidemiologie $x patofyziologie $7 D009369
- 650 _2
- $a hodnocení rizik $x metody $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dent, Susan $u Duke Cancer Institute, Duke University, Durham, NC, USA
- 700 1_
- $a Stanway, Susannah $u Breast Unit, Royal Marsden Hospital, Surrey, UK
- 700 1_
- $a Earl, Helena $u Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK
- 700 1_
- $a Brezden-Masley, Christine $u Division of Medical Oncology, Sinai Health System, Mount Sinai Hospital, Toronto, Canada
- 700 1_
- $a Cohen-Solal, Alain $u UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP, Paris, France
- 700 1_
- $a Tocchetti, Carlo G $u Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy
- 700 1_
- $a Moslehi, Javid J $u Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- 700 1_
- $a Groarke, John D $u Cardio-Oncology Program, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Bergler-Klein, Jutta $u Department of Cardiology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Khoo, Vincent $u Department of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, UK $u Department of Medical Imaging and Radiation Sciences, Monash University and Department of Medicine, Melbourne University, Melbourne, Australia
- 700 1_
- $a Tan, Li Ling $u Department of Cardiology, National University Heart Centre, Singapore, National University Health System, Singapore, Singapore
- 700 1_
- $a Anker, Markus S $u Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany
- 700 1_
- $a von Haehling, Stephan $u Department of Cardiology and Pneumology, University of Goettingen Medical Center, Goettingen, Germany $u German Center for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany
- 700 1_
- $a Maack, Christoph $u Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
- 700 1_
- $a Pudil, Radek $u First Department of Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic
- 700 1_
- $a Barac, Ana $u MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA
- 700 1_
- $a Thavendiranathan, Paaladinesh $u Ted Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada
- 700 1_
- $a Ky, Bonnie $u University of Pennsylvania, Philadelphia, PA, USA
- 700 1_
- $a Neilan, Tomas G $u Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Belenkov, Yury $u Sechenov Medical University, Moscow, Russia
- 700 1_
- $a Rosen, Stuart D $u Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK
- 700 1_
- $a Iakobishvili, Zaza $u Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Sverdlov, Aaron L $u School of Medicine and Public Health, University of Newcastle and "Cancer and the Heart" Program, Hunter New England LHD, Newcastle, Australia
- 700 1_
- $a Hajjar, Ludhmila A $u Cardio-Oncology, Department of Cardio-Pneumology, University of São Paulo, São Paulo, Brazil
- 700 1_
- $a Macedo, Ariane V S $u Santa Cardio-Oncology, Santa Casa de São Paulo and Rede Dor São Luiz, São Paulo, Brazil
- 700 1_
- $a Manisty, Charlotte $u Barts Heart Centre and University College London, London, UK
- 700 1_
- $a Ciardiello, Fortunato $u Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
- 700 1_
- $a Farmakis, Dimitrios $u University of Cyprus Medical School, Nicosia, Cyprus $u Cardio-Oncology Clinic, Heart Failure Unit, "Attikon" University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece $7 xx0281405
- 700 1_
- $a de Boer, Rudolf A $u Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- 700 1_
- $a Skouri, Hadi $u Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon
- 700 1_
- $a Suter, Thomas M $u Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
- 700 1_
- $a Cardinale, Daniela $u Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy
- 700 1_
- $a Witteles, Ronald M $u Stanford University School of Medicine, Stanford, CA, USA
- 700 1_
- $a Fradley, Michael G $u University of Pennsylvania, Philadelphia, PA, USA
- 700 1_
- $a Herrmann, Joerg $u Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Cornell, Robert F $u Vanderbilt University Medical Center, Nashville, TN, USA
- 700 1_
- $a Wechelaker, Ashutosh $u National Amyloidosis Centre, University College London, London, UK
- 700 1_
- $a Mauro, Michael J $u Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Milojkovic, Dragana $u Department of Haematology, Hammersmith Hospital, Imperial College, London, UK
- 700 1_
- $a de Lavallade, Hugues $u Department of Haematological Medicine, King's College Hospital, London, UK
- 700 1_
- $a Ruschitzka, Frank $u University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Coats, Andrew J S $u University of Warwick, Warwick, UK $u Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy
- 700 1_
- $a Seferovic, Petar M $u Faculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Chioncel, Ovidiu $u Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania $u University of Medicine Carol Davila, Bucharest, Romania
- 700 1_
- $a Thum, Thomas $u Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Bauersachs, Johann $u Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Andres, M Sol $u Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK
- 700 1_
- $a Wright, David J $u Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK
- 700 1_
- $a López-Fernández, Teresa $u Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain
- 700 1_
- $a Plummer, Chris $u Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, UK
- 700 1_
- $a Lenihan, Daniel $u Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA
- 773 0_
- $w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 22, č. 11 (2020), s. 1945-1960
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32463967 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20230131100510 $b ABA008
- 999 __
- $a ok $b bmc $g 1690643 $s 1140326
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 22 $c 11 $d 1945-1960 $e 20200806 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
- GRA __
- $a 06/303/98 $p Department of Health $2 United Kingdom
- GRA __
- $a P30 CA008748 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA233610 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 HL141466 $p NHLBI NIH HHS $2 United States
- LZP __
- $a Pubmed-20210728
